Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
April 27, 2021 10:29 AM EDT
Bioregnum

Now reimag­in­ing home, of­fice sched­ules: No­var­tis CEO Vas Narasimhan sees a new nor­mal in the post-Covid era

It’s not just small biotechs that are look­ing to com­plete­ly reeval­u­ate their need for of­fice space in a post-Covid world. It turns out No­var­tis CEO …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times